Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study

Portenoy, Russell K.; Messina, John; Xie, Fang; Peppin, John F.

doi:10.1185/030079906x162818

Cited by 96 publications

(79 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found that those patients who were simultaneously treated with asneeded and regularly scheduled opioids, a strategy for treating pain exacerbations, 7,8 did not have a statistically significant increased risk of opioid overdose in adjusted models. Recent treatment guidelines have indicated that the long-term safety of this strategy for pain exacerbation has not been established, 5,9 and in the present study we did not find evidence of greater overdose risk associated with this treatment practice after accounting for maximum daily dose and patient characteristics.…”

Section: Commentmentioning

confidence: 82%

Association Between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths

Bohnert

Valenstein

Bair

et al. 2011

JAMA

1,319

1,046

View full text Add to dashboard Cite

show abstract

Section: Commentmentioning

confidence: 82%

Association Between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths

Bohnert

Valenstein

Bair

et al. 2011

JAMA

1,319

1,046

View full text Add to dashboard Cite

show abstract

“…59,60 Because of methodological problems, valid estimates for efficacy of the intervention could not be determined, but adverse event rates among both treated populations were common and similar (range 63% to 65%) (Class III).…”

Section: In the Adult Ed Patient With An Acute Exacerbation Of Noncanmentioning

confidence: 99%

Clinical Policy: Critical Issues in the Prescribing of Opioids for Adult Patients in the Emergency Department

Cantrill

Brown

Carlisle

et al. 2012

Annals of Emergency Medicine

215

172

View full text Add to dashboard Cite

This clinical policy deals with critical issues in prescribing of opioids for adult patients treated in the emergency department (ED). This guideline is the result of the efforts of the American College of Emergency Physicians, in consultation with the Centers for Disease Control and Prevention, and the Food and Drug Administration. The critical questions addressed in this clinical policy are: (1) In the adult ED patient with noncancer pain for whom opioid prescriptions are considered, what is the utility of state prescription drug monitoring programs in identifying patients who are at high risk for opioid abuse? (2) In the adult ED patient with acute low back pain, are prescriptions for opioids more effective during the acute phase than other medications? (3) In the adult ED patient for whom opioid prescription is considered appropriate for treatment of new-onset acute pain, are short-acting schedule II opioids more effective than short-acting schedule III opioids? (4) In the adult ED patient with an acute exacerbation of noncancer chronic pain, do the benefits of prescribing opioids on discharge from the ED outweigh the potential harms?

show abstract

“…ized controlled trials evaluating fentanyl buccal tablet effectiveness have reported decreases in breakthrough pain intensity within 10 minutes of administration among patients with chronic low back pain [ 51 ] and chronic noncancer neuropathic pain [ 52 ]. Similarly, OTFC has been shown effective in treating chronic noncancer pain [ 53 ] and migraine pain [ 54 ].…”

Section: (Continued)mentioning

confidence: 97%

Assessment and management of breakthrough pain in cancer patients: Current approaches and emerging research

Hagen

Biondo²,

Stiles³

2008

Current Science Inc

View full text Add to dashboard Cite

Cancer pain is highly prevalent and often severe. Fortunately, most cancer pain can be readily managed, with up to 90% of patients responding well to standard interventions. However, breakthrough cancer pain-brief flares of severe pain superimposed on baseline pain-is common, difficult to manage, and often negatively impacts patients' quality of life. Breakthrough cancer pain is traditionally managed with oral, immediate-release opioids. However, because of its sudden onset and severity, oral opioids often fall short of providing adequate control. Research into novel approaches to pain management has identified several innovative strategies for this difficult cancer pain problem. We describe current approaches to assess, define, characterize, and treat breakthrough cancer pain, and summarize recent clinical research on novel agents, novel routes of drug delivery, and other advances in its management.

show abstract

Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study

Abstract: FBT was efficacious and well tolerated in the treatment of BTP in opioid-treated patients with chronic low back pain.

Cited by 96 publications

References 19 publications

Association Between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths

Association Between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths

Clinical Policy: Critical Issues in the Prescribing of Opioids for Adult Patients in the Emergency Department

Assessment and management of breakthrough pain in cancer patients: Current approaches and emerging research

Contact Info

Product

Resources

About